Scarica l'app Stockscreener
0.7975
44.23%
-0.6325
Dopo l'orario di chiusura:
.79
-0.0075
-0.94%
Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie
Verrica Pharmaceuticals Reports Q3 2024 EPS of -$0.49 and Revenue of -$1.9 Million, Misses Estimates - GuruFocus.com
Verrica Pharmaceuticals stock hits 52-week low at $0.93 - Investing.com
U.S. Stock market: Bluejay Diagnostics (+105.33%), Zoomcar Holdings (+180.40%), and Verrica Pharmaceuticals(+39.10%) among the most volatile stocks during mid day trading - Business Upturn
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Benzinga
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat
Verrica Pharmaceuticals stock hits 52-week low at $0.93 By Investing.com - Investing.com UK
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Royal Bank of Canada to "Sector Perform" - MarketBeat
Verrica Pharmaceuticals Appoints Jayson Rieger as New CEO - Marketscreener.com
Verrica Pharmaceuticals earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
Shares of Verrica Pharmaceuticals Tumble Following 3Q Results, Operational Changes - MarketWatch
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition - GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership - The Bakersfield Californian
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - Defense World
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Expands By 24.8% - MarketBeat
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - GlobeNewswire
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection - Law360
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Given New $10.00 Price Target at TD Cowen - MarketBeat
Verrica shares price target cut by TD Cowen - Investing.com Canada
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc.VRCA - Business Wire
GLP-1 Receptor Agonist Market Set to Witness Significant Growth by 2024-2031:Verrica Pharmaceuticals, AbbVie - EIN News
Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... - Yahoo Finance
Verrica Pharmaceuticals reports board changes, non-compliance - Investing.com India
Verrica Pharmaceuticals reports board changes, non-compliance By Investing.com - Investing.com Australia
Recent Insider Activity Could Benefit Verrica Pharmaceuticals Inc (VRCA) - Knox Daily
Verrica Pharmaceuticals Strives for Nasdaq Compliance - TipRanks
Optinose Names Terry Kohler as CFO - MarketWatch
Optinose names Terry Kohler as new CFO By Investing.com - Investing.com UK
Optinose Appoints Terry Kohler as Chief Financial Officer - Marketscreener.com
The Significance of Moving Averages in Verrica Pharmaceuticals Inc Inc. (VRCA) Price Performance - The InvestChronicle
Verrica Pharmaceuticals Inc (VRCA)’s stock price range in the last year - US Post News
Financial Fitness Check: Examining Verrica Pharmaceuticals Inc (VRCA)’s Key Ratios - The Dwinnex
Verrica Pharmaceuticals Inc [VRCA] Shares Fall Approximately -61.64% Over the Year - Knox Daily
Verrica Pharmaceuticals Inc [VRCA] Revenue clocked in at $13.91 million, down -80.19% YTD: What’s Next? - The DBT News
Royal Bank of Canada Cuts Verrica Pharmaceuticals (NASDAQ:VRCA) Price Target to $11.00 - MarketBeat
This Tractor Supply Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - MSN
Verrica downgraded to hold by Needham, cash position cited - MSN
Verrica Pharmaceuticals CEO to Present at Global Investment Conference - MSN
Madrigal Pharmaceuticals Joins H.C. Wainwright MASH Virtual Investor Conference - MyChesCo
The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49% - Simply Wall St
Verrica Pharmaceuticals’ (VRCA) Hold Rating Reaffirmed at Needham & Company LLC - Defense World
A new trading data show Verrica Pharmaceuticals Inc (VRCA) is showing positive returns. - SETE News
Verrica Pharmaceuticals Announce Restructuring - citybiz
Verrica Pharmaceuticals Streamlines Operations to Enhance YCANTH Access - MSN
Verrica slashes costs, refocuses sales strategy By Investing.com - Investing.com South Africa
Verrica slashes costs, refocuses sales strategy - Investing.com
Verrica Pharmaceuticals announces workforce reduction By Investing.com - Investing.com Australia
Verrica Pharmaceuticals' (VRCA) Hold Rating Reiterated at Brookline Capital Management - MarketBeat
Verrica Pharmaceuticals’ (VRCA) “Hold” Rating Reiterated at Brookline Capital Management - Defense World
Verrica Pharmaceuticals Inc (VRCA) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization - The Manila Times
Verrica Pharmaceuticals announces workforce reduction - Investing.com India
A company insider recently sold 26,183 shares of Verrica Pharmaceuticals Inc [VRCA]. Should You also Consider to Sale? – Knox Daily - Knox Daily
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):